Literature DB >> 32887991

Immunosenescence and Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.

David Nalin1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32887991      PMCID： PMC7499681          DOI： 10.1093/infdis/jiaa564

Source DB:  PubMed          Journal:  J Infect Dis        ISSN： 0022-1899            Impact factor:   5.226


× No keyword cloud information.
  4 in total

1.  Risks of adverse outcomes in COVID-19 patients and vaccination status in a secondary hospital in Spain.

Authors:  Christine Giesen; Carmen Saa-Requejo; Inmaculada Lopez-Carrillo; Angelica Ortega-Torres; Cristina García-Fernández
Journal:  Vacunas       Date:  2022-05-30

2.  Clinical Features and Time to Recovery of Admitted COVID-19 Cases at Dilla University Referral Hospital Treatment Center, South Ethiopia.

Authors:  Gemechu Churiso; Kuma Diriba; Henok Girma; Soressa Tafere
Journal:  Infect Drug Resist       Date:  2022-03-04       Impact factor: 4.003

3.  Effects of 3 months of multi-nutrient supplementation on the immune system and muscle and respiratory function of older adults in aged care (The Pomerium Study): protocol for a randomised controlled trial.

Authors:  Ahmed Al Saedi; Ben Kirk; Sandra Iuliano; Jesse Zanker; Sara Vogrin; Lata Jayaram; Shane Thomas; Christine Golding; Diana Navarro-Perez; Petra Marusic; Sean Leng; Ralph Nanan; Gustavo Duque
Journal:  BMJ Open       Date:  2022-05-06       Impact factor: 3.006

Review 4.  The Interplay between Immunosenescence and Microbiota in the Efficacy of Vaccines.

Authors:  Rossella Cianci; Laura Franza; Maria Grazia Massaro; Raffaele Borriello; Francesco De Vito; Giovanni Gambassi
Journal:  Vaccines (Basel)       Date:  2020-11-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.